Articles From: Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Nymox Pharmaceutical Corporation -- NYMX to Galena Biopharma to Present at the Oppenheimer 25th Annual Healthcare Conference


2014/11/26
NEW YORK, Nov.
Sign-up for Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against SandRidge Energy, Inc. investment picks
http://media.marketwire.com/attachments/201411/288786_logoGALAGlobal.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1156849&ProfileId=051205&sourceType=1 LOS ANGELES, CA --
Sign-up for Gala Global, Inc. Plans for New Products and Service From Hemp and Cannabis investment picks
2014/9/26
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1147556&ProfileId=051205&sourceType=1 NEW ORLEANS, LA --
Sign-up for GALECTIN 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against Galectin Therapeutics Inc. - GALT investment picks
NORCROSS, Ga., Dec.
Sign-up for Galectin Therapeutics to Present at 7th Annual LD Micro Main Event Conference investment picks
Initial Purchase of $5.0 Million at $2.00 per share, 9% higher than the market close as of November 18, 2014 Agreement structure provides Galena control and flexibility to access capital over the long-term to fund the Company's clinical and development programs PORTLAND, Ore., Nov.
Sign-up for Galena Biopharma Announces Purchase Agreement for Up to $55.0 Million With Lincoln Park Capital Fund, LLC investment picks
Enrollment completed six months ahead of schedule Phase 1 and early Phase 2 data to be presented at the American Society of Hematology 56 th Annual Meeting in December, with top-line data in mid-year 2015 PORTLAND, Ore., Nov.
Sign-up for Galena Biopharma Completes Enrollment in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial investment picks
Trial expands the eligible patient population and overall NeuVax clinical trial portfolio Recent patent allowance provides intellectual property protection for NeuVax in combination with Herceptin in any HER2/neu expressing cancer PORTLAND, Ore., Nov.
Sign-up for Galena Biopharma Doses First Patient in Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Combination With Herceptin(R) (trastuzumab) to Treat High-Risk HER2 3+ or HER2 Gene-Amplified Breast Cancer Patients investment picks
Preliminary data shows a 31% recurrence rate in the vaccine group compared to 50% in the control group at a median follow up of 13 months, a 38% reduction in relative risk of recurrence GALE-301 plus GM-CSF is well tolerated and elicits a strong in vivo immune response with primarily Grade 1 and Grade 2 toxicities Top-line data to be presented mid-year 2015 PORTLAND, Ore., Nov.
Sign-up for Galena Biopharma Presents GALE-301 (Folate Binding Protein Immunotherapy) Phase 2a Clinical Trial Data at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting investment picks
Phase 1 results demonstrate GALE-401 reduces platelet counts with tolerable safety profile Preliminary Phase 2 clinical trial data show promising platelet response with top-line data to be presented mid-year 2015 PORTLAND, Ore., Dec.
Sign-up for Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition investment picks
- Allowed claims will cover the use of NeuVax alone or in combination to prevent recurrence of any breast cancer tumor expressing low-to-intermediate levels of HER2 - Extends patent coverage to three main markets, U.S., EU and now Japan PORTLAND, Ore., Oct.
Sign-up for Galena Biopharma Receives Notice of Allowance of Improvement Patent for NeuVax(TM) (nelipepimut-S) in Japan investment picks
Clinical programs advance on multiple fronts, with trial initiation, trial enrollment, data and IP milestones achieved and anticipated Commercial strategy reinforced with product acquisition and upcoming commercial launch Abstral ® (fentanyl) sublingual tablet net revenue was $1.6 million in Q3 2014 and $6.1 million to date this year, with reiterated guidance of $8-$10 million for the full year 2014 Zuplenz ® (ondansetron) Oral Soluble Film U.S. rights licensed; launch expected in Q1 2015 Conference call scheduled for 5:00 pm E.T. today with details below PORTLAND, Ore., Nov.
Sign-up for Galena Biopharma Reports Third Quarter 2014 Results investment picks
PORTLAND, Ore., Nov.
Sign-up for Galena Biopharma to Present at the Oppenheimer 25th Annual Healthcare Conference investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Nymox Pharmaceutical Corporation -- NYMX to Galena Biopharma to Present at the Oppenheimer 25th Annual Healthcare Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent